Abstract

A new biotechnology based on micro-needling (MND) with low-level light/laser therapy (LLLT) that is used for hair re-growth (HR-G) needs to be standardized. The study aims to report the clinical outcomes resulting from a multicentric, retrospective, observational, case-series study in which MND with LLLT was used on patients affected by androgenic alopecia (AGA). Twenty-six patients were initially enrolled of which 15 males were classified as stages I–III of vertex by the Norwood–Hamilton scale, and 11 females was classified in stages I–II by the Ludwig scale. Twenty patients (10 females and 10 males) were analyzed after their screening (the exclusion and inclusion criteria evaluation). The HR-G assessment was evaluated with photography, as well as the physician’s and patient’s global assessment scales, in addition to standardized phototrichograms, during a short follow-up at T0-baseline, T1-16 weeks. Encouraging results represented by a hair density increase of 12 ± 2 hairs/cm2 at T1 after 16 weeks (16 weeks vs. 0 weeks) in the targeted area, compared with the baseline results (59 ± 2 hairs/cm2 at T1 versus 47 ± 2 hairs/cm2 at baseline), were observed using computerized trichograms with a statistically significant difference in hair re-growth (p = 0.0238). The effectiveness of MND with LLLT use has been demonstrated in mild to moderate AGA patients.

Highlights

  • Scientific research in the regenerative field exists even for the development of miniinvasive biotechnologies aimed to enhance hair re-growth (HR-G) in patients suffering from androgenetic alopecia (AGA)

  • The number of papers evaluating the effectiveness of low-level light/laser therapy (LLLT) in male pattern hair loss (MPHL) and/or female pattern hair loss (FPHL) has exponentially increased during the last decade

  • treatments at weeks (T1) after 16 weeks (16 wks vs. 0 wks) (Figure 4B) in the targeted areas (TA) compared with the baseline (Figure 4A)

Read more

Summary

Introduction

Scientific research in the regenerative field exists even for the development of miniinvasive biotechnologies aimed to enhance hair re-growth (HR-G) in patients suffering from androgenetic alopecia (AGA). AGA is one of the most important and frequent hair loss (HL) causes affecting a mean of 80% of white men and 40% of women, determining, respectively, a male pattern hair loss (MPHL) and a female pattern hair loss (FPHL) [1,2,3,4]. The number of papers evaluating the effectiveness of low-level light/laser therapy (LLLT) in MPHL and/or FPHL has exponentially increased during the last decade (2011–2021). The purposed mechanism of LLLT in HR-G is the stimulation of mitochondria located in the hair bulge stem cells. Reactive oxygen species (ROS) and adenosine triphosphate (ATP) stimulate cellular proliferation, migration, and oxygenation, which, promotes hair growth [6]. In 2007, the first cleared LLLT device was introduced for MPHL by the US

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call